CMR Surgical Names Supratim Bose as New CEO

Surgical robotics company CMR Surgical has named Supratim Bose as its new CEO, taking over for Per Vegard Nerseth immediately.
 
Bose joined CMR in February 2023 as senior adviser to the CEO, assuming leadership of the Asia, Middle East, and Africa region. He has over 40 years of leadership experience in the medical device industry, including leadership roles with Johnson & Johnson, Boston Scientific, and ConvaTec.
 
As new CEO, Bose will oversee the company’s global rollout of its Versius surgical robotic system. CMR has operations in over 20 markets. Versius is a small, versatile, modular, and portable surgical robot. It lets surgeons perform fully robotic and as well as a combination of robotic and manual laparoscopic procedures.
 
Umur Hursever, on behalf of the Board of CMR Surgical, told the press: “We are delighted to have someone of Supratim’s experience leading CMR. CMR has a very powerful mission to bring minimal access surgery to everyone who needs it, and given Supratim’s exceptional track record leading global MedTech businesses I am excited to work with him and the leadership team to continue to disrupt the market. I would like to thank Per Vegard for his contributions to CMR and wish him well for the future.”
 
Supratim Bose said: “With Versius we have an opportunity to help hospitals and surgeons transform surgery for people around the world. I am excited to lead a business that has such a differentiated product with Versius, that is addressing a high unmet need for better surgical care around the world. I look forward to working with everyone at CMR to bring the benefits of surgical robotics to hospitals and surgeons around the world.”
 
Per Vegard Nerseth said: “During my time at the company I am proud to have seen CMR expand its commercial operations and bring Versius into the hands of more surgeons and hospitals. After experiencing strong growth, CMR is now the second largest surgical robotics company on the market with a significant presence across four continents. I look forward to seeing the company continue to grow so that more hospitals and patients can benefit from minimal access surgery.”